RxDoctor Payments Data

Laura Baehner, MD

Psychiatry · Medical Lake, WANPI 1003990516

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,717in general payments, 2019–2025

Across 157 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$477
  • Johnson & Johnson$343
  • Otsuka America Pharmaceutical, Inc.$313
  • Teva Pharmaceuticals USA, Inc.$247
  • AbbVie$205
  • Axsome Therapeutics, Inc.$177
  • plus $954 from 7 others

What the payments were for

  • Food & beverage$2,65498%
  • Education$632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,717 in reported general payments places this provider in the 90th percentile of 576 psychiatry providers in Washington.

See all psychiatry providers in Washington

Medicare billing

Part B allowed, 2024
$24,540
Medicare patients
35
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$158,917
CaplytaLumateperone Tosylate13$31,928
VraylarCariprazine Hcl12$16,711
Aripiprazole60$5,110
Duloxetine Hcl159$3,270
Bupropion XlBupropion Hcl137$2,176
Olanzapine82$2,088
Buspirone Hcl62$1,792
Trazodone Hcl158$1,735
Quetiapine Fumarate94$1,614
Ziprasidone Hcl15$1,387
Divalproex Sodium ErDivalproex Sodium24$1,377
Lamotrigine137$1,332
Venlafaxine Hcl ErVenlafaxine Hcl58$1,285
Paliperidone ErPaliperidone15$1,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$247$158,91712 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$477$31,92813 claims
AbbVieVraylar$205$16,71112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 576 psychiatry providers in Washington.

Other psychiatry in Medical Lake

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →